CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Activation of First Clinical Trial Sites in Europe Evaluating Berubicin for the Treatment of GBM
CNS Pharmaceuticals (NASDAQ: CNSP) has announced the activation of its first clinical trial sites in Europe for a pivotal global trial of Berubicin, a treatment for recurrent glioblastoma multiforme (GBM). This action supports the ongoing evaluation of Berubicin's efficacy and safety against the standard care, Lomustine. The FDA has granted Fast Track and Orphan Drug Designations for Berubicin, accelerating its development process. CEO John Climaco emphasized the commitment to advancing this clinical program and the urgency of addressing the unmet needs in GBM.
- First clinical trial sites in Europe activated for Berubicin.
- FDA Fast Track Designation granted for Berubicin, enabling expedited development.
- Received Orphan Drug Designation, providing potential seven years of marketing exclusivity upon approval.
- None.
LOS ANGELES, Oct. 07, 2022 (GLOBE NEWSWIRE) -- InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio news release covers CNS Pharmaceuticals’ recent announcement highlighting the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), one of the most aggressive types of brain cancer.
To hear the audio production, visit: https://www.nnw.fm/TCHxT
To read the original press release, visit: https://nnw.fm/js5dD
“Our primary focus continues to be on advancing the clinical development of Berubicin as a potential treatment option for this devastating disease. Over the course of this year, we have worked diligently to expand patient eligibility for our potentially pivotal trial and bolster our international presence now realized with the activation of the first two European clinical trial sites,” John Climaco, CEO of CNS Pharmaceuticals, stated in the news release. “This is a true testament to our team's commitment to and the execution of this important clinical program.”
Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently being evaluated in a potentially pivotal global study evaluating its efficacy and safety in the treatment of GBM. The potentially pivotal trial is an adaptive, multicenter, open-label, randomized and controlled study in adult patients with recurrent glioblastoma multiforme (WHO Grade IV1) after failure of standard first-line therapy. The primary endpoint of the study is Overall Survival (OS), which is a rigorous endpoint that the FDA has recognized as a basis for approval of oncology drugs when a statistically significant improvement can be shown relative to a randomized control arm. Results from the trial will compare Berubicin to a current standard of care (Lomustine), with a 2 to 1 randomization of patients to receive either Berubicin or Lomustine.
“We are grateful for the tremendous support from the clinical staff and remain dedicated to driving patient enrollment as quickly and efficiently as possible. We look forward to continuing to build momentum and bringing Berubicin across the finish line to unlock its greatest potential. As long as the unmet medical need in GBM remains, we will continue our fight in earnest to bring hope to patients and families globally,” Climaco added.
As detailed in the news release, the FDA has granted CNS Pharmaceuticals Fast Track Designation for Berubicin, which enables more frequent interactions with them to provide guidance on expediting the development and review process. Additionally, the company has also received Orphan Drug Designation from the FDA, which may provide seven years of marketing exclusivity upon approval of an NDA.
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and connect with the company on Twitter, Facebook, and LinkedIn.
About NetworkNewsAudio
NetworkNewsAudio (“NNA”), one of 50+ brands within IBN (InvestorBrandNetwork), allows you to sit back and listen to market updates, CEO interviews and AudioPressRelease (“APR”) productions. These audio clips provide snapshots of position, opportunity and momentum. NNA can assist by cutting through the overload of information in today's market, while bringing its clients unparalleled visibility, recognition and brand awareness. IBN is where news, content and information converge. IBN is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, IBN has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of 5,000+ key syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer
Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of enrollment of new patients and the ability of the Company to complete the trial on a timely basis, if at all. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
